| NCT07084584 | An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NOT_YET_RECRUITING | PHASE1, PHASE2 | 2026-06-10 | 2029-10-10 | 2029-06-10 |
| NCT05747573 | A Study to Compare Pharmacokinetics of GB1211 | COMPLETED | PHASE1 | 2023-01-03 | 2023-04-10 | 2023-04-10 |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-03-15 | 2025-11-01 | 2024-05-30 |
| NCT05009680 | A Single and Repeat Dose Trial in Participants With Hepatic Impairment | UNKNOWN | PHASE1, PHASE2 | 2021-09-09 | 2023-07-04 | 2022-07-18 |
| NCT04679870 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-06-09 | 2026-06-30 | 2023-12-31 |
| NCT04607655 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis | WITHDRAWN | PHASE1, PHASE2 | 2021-03 | 2022-07 | 2022-07 |
| NCT03832946 | A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | PHASE2 | 2019-02-19 | 2023-05-17 | 2023-05-17 |
| NCT03809052 | A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects | COMPLETED | PHASE1 | 2019-01-14 | 2019-06-25 | 2019-06-25 |
| NCT02257177 | RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients | COMPLETED | PHASE1, PHASE2 | 2014-09 | 2016-12 | 2016-12 |